Aji Bio-Pharma Expands Agreement with AstraZeneca to Include Drug Product Manufacturing
The expanded agreement will include aseptic fill/finish services at its San Diego, CA facility.
Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), announced on March 30, 2021 that it has expanded its manufacturing agreement with AstraZeneca to include drug product manufacturing.
According to an Aji Bio-Pharma press release, the expanded agreement will include aseptic fill/finish services at its San Diego, CA facility, in addition to the small molecule manufacturing services already performed in Belgium.
"We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings," said Magnus Busch, global account manager, Ajinomoto Bio-Pharma Services, in the press release. "Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients."
Source: Aji Bio-Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
